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Abstract
Aim: to analyze the influence of the immunomodeling preparation glutamyl-cysteinyl-glycine disodium (glutoxim) on in-
dices of cellular and humoral immunity in patients with pneumonias on the background of acute myeloblast leucosis to form new 
approaches to the improvement of treating pneumonias in patients with immunity disorders. 
Materials and methods. The research group − 37 patients with pneumonia on the background of acute myeloblast leucosis, 
who underwent the program treatment on the base of the hematological center “MI city multi-profile clinical hospital No. 4” Dnipro 
city, 2014−2015. The age of patients from 23 to 45 years old; 10 women and 27 men. The diagnosis of leucosis and pneumonia forms 
was verified corresponding to modern conventional clinical and morphological criteria. Patients from the main research group (n=18) 
were prescribed with glutamyl-cysteinyl-glycine disodium by the scheme 2 ml of 3 % (60 mg) i/v No. 10 in mornings, summary 
dose − 300 mg. Indications of immunograms were studied: Т-lymphocytes, В-lymphocytes and their subpopulation composition 
(CD3+, CD4+, CD8+, CD19+, CD19−, CD16+, CD56+) using the flowing laser cytofluorimetry. Immunoglobulin levels were deter-
mined by the method of immunoturbometry. Indications of immunograms were assessed in the treatment dynamics. The statistical 
processing – using packages of applied programs «Excel» and «Statistic 10».
Results. According to the analysis of indices of the cellular and humoral immunity of patients with pneumonia on the 
background of acute myeloblast leucosis, the process of glutamyl-cysteinyl-glycine disodium use proved the statistically reliable 
activation of phagocytosis and anti-infectious defense indices. The dynamics of humoral immunity indices also proved the positive 
influence on the state of the immune reactivity of the organism with the reliable increase of ІgА and Іg М, responsible for neutraliza-
tion of infectious agents and bacterial toxins. 
Conclusions: The use of the ummunomodeling preparation glutamyl-cysteinyl-glycine disodium (glutoxim) in patients with 
pneumonia on the background of acute myeloblast leucosis results in the improvement of indices of cellular and humoral immunity 
and phagocytosis activation. The research results prove the possibility of optimization of approaches to treating pneumonias in pa-
tients with severe immunity disorders by using immunomedeling therapy by glutamyl-cysteinyl-glycine disodium (glutoxim). 
Keywords: pneumonia, myeloblast leucosis, glutamyl-cysteinyl-glycine disodium, cellular and humoral immunity indices. 
DOI: 10.21303/2504-5679.2017.00430 © Inna Borisova
1. Introduction
The pathogenetic background of acute leucosis (AL) is a cellular immunity defect, mani-
fested by the change of quantitative indices and functional disability of Т-lymphocytes and mono-
cytic-phagocytic system. Immunity disorders in patients with AL are conditioned also by treating 
methods. The wide use of anti-tumor chemotherapy at AL leads to different side effects. Infectious 
complications remain the most often and most severe among all ones in oncohematologic patients 
during the program treatment, and are often the direct cause of their death [1]. Corticosteroids, 
combined with cytostatics negatively influence the patient’s immunity state. On this background 
severe infectious-inflammatory complications, including pneumonias that often result in patients’ 
death are observed in patients with AL in more than 50 % cases [2]. The incorrect antibacterial 
therapy also intensifies the expressiveness of the immunodeficiency syndrome and leads to the for-
mation of resistant nosocomial flora that is very difficultly subjected to elimination in patients with 
pneumonia on the background of AL [3]. In this connection the strategy of using only etiotropic 
antibacterial therapy (ABT) at pneumonias in patients with AL doesn’t lead to expected results. 
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For increasing the effectiveness of treating pneumonia in patients with AL, immunotherapy which 
main aim – to help the immune system to attack tumor cells by the immunity stimulation, is used 
more and more often in the last years. 
Glutamyl-cysteinyl-glycine disodium – is a chemically synthesized biologically active com-
pound – hexapeptide with the stabilized disulphide connection (bis-(gamma-L-glumamyl)-cyste-
inyl-bis-glycine-disodium salt) with the general formula − С20H32O16N6S2. This preparation is a rep-
resentative of the new class of medical substances – tiopoetins that regulate genetic and metabolic 
processes in cells and tissues, influencing immune resistance due to the modeling influence on 
intracellular processes of thiol metabolism [4]. The special feature of the preparation is the ability 
to the differentiated influence on normal and transformed (blastic, tumor) cells. The preparation 
doesn’t disturb regulatory relations between humoral and cellular immunity links [4]. The analysis 
of clinical researches proves positive results of using this preparation in patients with oncologic 
diseases [5]. The normalizing influence of the preparation on the cellular regulation reaction, ox-
ygen delivery to cells, intensity of the oxidative cellular metabolism, combined with the inflow of 
necessary amino acids causes the increase of normocytes resistance to endogenous and microbial 
toxins, chemotherapy (CT) components, favors the better course of the program therapy and faster 
treating effect in the clinic of the oncologic pathology [6]. Modern scientific studies in pulmon-
ology also demonstrate the positive influence of glutamyl-cysteinyl-glycine disodium at chronic 
specific [7] and non-specific [8] pulmonary diseases including pneumonias [9]. We know studies 
that use functional changes of the immune reactivity state as indications for the beginning of ABT 
correction at pneumonias [10]. Some authors demonstrated the contribution of this preparation in 
more bio-availability to the effect of antibacterial preparations [11]. Scientific studies proved that 
glutamyl-cysteinyl-glycine disodium is the choice preparation for potentiation of the antibacterial 
effect of chemotherapeutic preparations and decrease of antibacterial resistance [11].
The diversity of intracellular and humoral regulatory effects of glutamyl-cysteinyl-glycine 
disodium, its positive influence on all links of the immune response in patients with leucosis with 
pneumonia manifestations and its possibility to influence non-differentiated malignant cells of the 
main disease, determined the choice of this preparation for elaborating the treating method of pneu-
monia in patients on AL background. 
2. Aim of research
To analyze the influence of the immunomodeling preparation glutamyl-cysteinyl-glycine 
disodium on cellular and humoral immunity indices in patients with pneumonia on the background 
of AnonLL for forming new approaches to the improvement of treating pneumonias in patients 
with immunity disorders. 
3. Materials and methods
The research group consisted of 37 patients with pneumonia, developed at the background 
of AnonLL, who underwent the program treatment according to the form and stage of the disease 
on the base of the hematological center “MI of city multi-profile clinical hospital No. 4”, Dnipro 
city. The age of patients from the research groups was from 23 to 45 years; among them – 10 women 
and 27 men. The diagnosis of acute non-lymphoblast leucosis (AnonLL) was verified according to 
conventional clinical and morphological criteria, treatment protocol – 7+3 [12]; the diagnosis of 
pneumonia was verified according to modern clinical protocols of diagnostics and treatment [13]. 
Patients were divided in two groups. Patients of the main research (n=18) were addition-
ally prescribed with glutamyl-cysteinyl-glycine disodium by the scheme 2 ml of 3 % solution 
(60 mg) i/v No. 5 each second day, on the background of the traditional ABT according to stan-
dards of pneumonia treatment. Preparation administration in morning hours, summary dose was 
300 mg. Patients of comparison (n=19) underwent the pneumonia treatment without immunomod-
eling preparations inclusion. The man age of the main group was 28,0 (24,5; 34,5) years, age of 
patients from the group of comparison – 29,5 (24,5; 32,5) (Me (25 %; 75 %)). The number of men 
and women in the main group – 3 and 15; in the control one – 5 and 14, respectively. The control 
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group contained 20 practically healthy donors (10 men and 10 women), which immunogram indices 
were compared with ones of the immune reactivity of patients at the end of treatment. 
All patients underwent the study of immune response indices. The determination of cellular 
immunity indices (Т-lymphocytes, В-lymphocytes and subpopulation composition (CD3+, CD4+, 
CD8+, CD19+, CD16+, CD56+) was realized using the flowing laser cytofluorimetry (Beckman-
Coulter-USA). The immunoregulatory index of T-helpers (СD3+СD4+)/Т cytotoxic (СD3+СD8+), 
leuco Т-cellular (leucocytes/CD3+), leuco В-cellular (leucocytes/CD19+), and the activation index 
of leucocytes (СD3+HLA-DR+) were additionally assessed. For assessing the functional-metabol-
ic activity of blood neutrophils there were studied: phagocytic number (PN) and phagocytic in-
dex (PI). The state of neutrophils oxygen killing was assessed by the results of the spontaneous 
NBT-test with nitrablue tetrazolium. The study of humoral immunity indices was realized by de-
termining immunoglobulins of A, G, M classes by the method of simple radial immunodiffusion. 
The research material was venous blood, taken from the cubital vein in morning only at the empty 
stomach, in the vacuum system to the set mark. K2ЕDТА was used as a coagulant. For obtaining 
correct results, according to the research method, after taking blood, the test tube with a sample 
was slowly turned 8–10 times for mixing blood with coagulant. It was stored and transported to the 
laboratory at the temperature 18−23 °С in the vertical position during 2−4 hours (maximally per-
mitted no more than 1 day). Indications of immunograms of patients from the research group were 
assessed in the treatment dynamics. There were also assessed: the clinical course of the disease, 
period of the intoxication syndrome regression, period of the body temperature normalization, dy-
namics of key indications of the hemogram, dynamics of rontgenological picture, general number 
of ABT days, necessity in its modification and possibility to return to the program treatment of the 
main disease depending on AnonLL stage. The statistical processing of research results was real-
ized using methods of the descriptive and analytic biostatistics, realized in packages of program 
products STATISTICA 6.1 (StatSoftInc., serial No. AGAR909E415822FA); Microsoft Excel (Office 
Home Business 2KB4Y-6H9DB-BM47K-749PV-PG3KT) with the program superstructure AtteS-
tat; program package MedCalc Statistical Software trial version 17.4. For describing quantitative 
signs, the median (Me) was used as a measure of the central tendency; interquartile scale ((25 %; 
75 %) – 25 and 75 percentiles correspondingly Q1 and Q3 – first and third quartiles) for describing 
signs variations; 95 % reliable interval (95 % RI) for determining the diapason of median values in 
the general totality. The assessment of the reliability of differences of mean values for quantitative 
signs, taking into account their mainly asymmetric distribution, was realized by Mann-Whitney 
criteria (U) for non-connected samples and Wilcoxon criterion (W) for connected samples. The 
statistically reliable value of the significance level was considered as p<0,05 (5 %) [14]. 
4. Results of research
The mean age of patients from the main group was 28,0 (24,5; 34,5) years, patients of 
the comparison group – 29,5 (24,5; 32,5). These indices didn’t essentially differ in the research 
groups (р=0,995). In the main group and comparison one were: patients in the stage “prima-
ry attack” – 8 and 7; in the stage “remission” – 9 and 11, respectively; in the stage “repeated 
relapse” – 1 and 1 patients. Pneumonia characteristics: in the main and comparison groups of 
patients pneumonia appeared on the background of neutropenia – in 7 and 8 patients; on the 
background of anemia of І−ІІ degree – in 5 and 6 patients; on the background of ІІІ−ІV de-
gree – in 13 and 13 patients, respectively. Patients with one-side lesion of lungs in the main 
group and comparison one: 7 and 7 patients; with two-side lesion of lungs: 11 and 12 patients, 
respectively; with pleurisy – 5 and 6 patients, respectively. Pneumonia was diagnosed during 
5 days of staying at hospital in the main and comparison groups: in 8 and 9 patients; after 
5 days of staying in 10 and 10 patients, respectively. Thus, the analysis of comparability of 
comparison groups proved their homogeneity by gender-age parameters that allow to compare 
them correctly by other studied parameters. 
The results of the study of cellular and humoral immunity indices and phagocytosis state of 
patients with AnonLL at the initial stage of pneumonia treatment are presented in Table 1. 
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Table 1
Cellular and humoral immunity indices and phagocytosis state of patients with nonLL at the initial stage of 
pneumonia treatment 
Indices Me (25 %; 75 %) Main group  n=18
Comparison group 
n=19
Control group  
n=20
Differences  
between groups*
Leucocytes, (109/l ) 2,56 (1,38; 3,45) 2,94 (1,74; 3,79) 6,11 (4,22; 8,46) р1=0,330; р2<0,001; р3<0,001
Lymphocytes, % 26,92 (24,4; 30,04) 29,15 (24,15; 35,35) 34,7 (33,71; 35,78) р1=0,176; р2<0,001; р3=0,004
В-cells
(СD3–СD19+), % 
10,42 (9,43; 11,86) 9,4 (7,5; 12,7) 17,22 (13,46; 19,38) р1=0,228; р2<0,001; р3<0,001
В-cells 
(СD3–СD19+), G/l 
0,18 (0,13; 0,4) 0,13 (0,09; 0,26) 0,44 (0,32; 0,52) р1=0,046; р2<0,001; р3<0,001
Т-cells (СD3+СD19–), % 52,03 (43,98; 56,14) 54,95 (45,65; 58,45) 71,79 (65,52; 75,31) р1=0,381; р2<0,001; р3<0,001
Т-cells (СD3+СD19–), G/l 1,1 (0,89; 1,78) 1,04 (0,57; 1,26) 1,41 (1,06; 1,73) р1=0,064; р2=0,363; р3=0,014
T-helpers (СD3+СD4+), % 30,29 (28,39; 34,22) 28,4 (24,6; 32,2) 38,13 (36,51; 41,5) р1=0,147; р2<0,001; р3<0,001
T-helpers (СD3+СD4+), G/l 0,72 (0,66; 0,94) 0,65 (0,5; 1,04) 0,91 (0,58; 1,09) р1=0,394; р2=0,517; р3=0,132
Т-cytotoxic (СD3+СD8+), % 22,61 (19,73; 27,42) 21,95 (19; 26,25) 28,05 (23,43; 29,88) р1=0,606; р2=0,003; р3=0,001
Т-cytotoxic (СD3+СD8+), G/l 0,55 (0,44; 0,77) 0,29 (0,21; 0,42) 0,46 (0,41; 0,57) р1<0,001; р2=0,021; р3<0,001
Immunoregulatory index 1,33 (1,01; 1,91) 1,3 (1,23; 1,44) 1,86 (1,28; 2,35) р1<0,661; р2=0,003; р3=0,008
NK-cells (СD3-СD16+СD56+), % 8,39 (9,53; 11,1) 7,81 (6,3; 12,95) 13,71 (9,71; 18,73) р1=0,105; р2=0,010; р3<0,001
NK-cells (СD3-СD16+СD56+), G/l 0,11 (0,10; 0,18) 0,12 (0,11; 0,19) 0,39 (0,25; 0,52) р1=0,815; р2=0,708; р3<0,001
T-NK-cells 
(СD3+СD16+СD56+), % 
3,31 (2,5; 4,2) 3,36 (2,5; 4,3) 2,21 (1,49; 4,28) р1=0,915; р2=0,608; р3=0,445
T-NK-cells 
(СD3+СD16+СD56+), G/l
0,042 (0,032; 0,05) 0,04 (0,03; 0,05) 0,03 (0,01; 0,04) р1=0,204; р2=0,207; р3=0,146
T-activated (СD3+HLA-DR+), % 2,07 (1,18; 3,9) 2,41 (1,3; 3,95) 3,33 (1,48; 5,26) р1=0,355; р2=0,074; р3=0,301
Іg А, g/l 1,49 (1,24; 2,04) 1,42 (1,05; 1,61) 2,94 (2; 3,27) р1=0,204; р2<0,001; р3<0,001
Іg М, g/l 0,9 (0,79; 1,1) 1,0 (0,56; 1,17) 1,55 (1,28; 1,89) р1=0,424; р2<0,001; р3<0,001
Іg G, g/l 9,21 (8,21; 10,95) 9,0 (6,17; 10,3) 10,24 (8,58; 11,92) р1=0,175; р2=0,237; р3=0,020
Phagocytic activity, un 26 (23; 28) 28,5 (22; 37,5) 60,83 (47,55; 73,01) р1=0,251; р2<0,001; р3<0,001
Phagocytic number, un 3,4 (2,7; 4,1) 3,0 (2,3; 4,1) 6,57 (4,84; 8,23) р1=0,456; р2<0,001; р3<0,001
Spontaneous NBT-test, un 5 (4; 6) 4 (3; 5) 8,63 (6,33; 12,29) р1=0,004; р2<0,001; р3<0,001
Stimulated NBT-test, un 24 (18; 27,5) 23,5 (15,5; 26,5) 63,69 (57,51; 68,36) р1<0,061; р2<0,001; р3<0,001
Note: * – differences between groups by Mann-Whitney U-criterion: р1 – between the main group and comparison one; р2 – between 
the main group and control one; р3 – between the comparison group and control one
As it can be seen on the table 1 there were observed no differences by indices of cellular 
and humoral immunity and phagocytosis state of patients of AnonLL research groups at the initial 
stage of pneumonia treatment. The decrease of the quantity of lymphocytes, T-helpers, T-inductors 
and T-cytoxic subpopulations and also B-lymphocytes and NK-cells was observed in both groups 
of patients. The obtained results coincide with data of other researchers [15]. It is understood, that 
comparing with the control group (healthy donors), most cellular and humoral immunity indices in 
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patients of research groups reliably differed in relative values (р1<0,001), that testified to the 
evident disorder of all immunity links in patients with AnonLL. Any differences were not ob-
served only by indices: T-helpers (СD3+СD4+) G/L, T-NK-cells (СD3+СD16+СD56+), T-acti-
vated (СD3+HLA-DR+) %, that proved the impossibility of the inhibited immunity activation 
in patients with AnonLL as a response to pneumonia. Just the activation of these indicators 
must be manifested in patients with acute infectious complications (IC), including patients 
with pneumonias. 
The research results of cellular immunity indices of patients with AnonLL at the final stage 
of pneumonia treatment at the background of pneumonia treatment with glutamyl-cysteinyl-gly-
cine disodium are presented in Table 2. 
Table 2
Cellular immunity indices of patients with AnonLL at the final stage of pneumonia treatment
Indices Me (25 %; 75 %) Main group  n=18
Comparison group 
n=19
Control group 
n=20 Differences between groups *
Leucocytes, 109/l 5,25 (4,79; 7,74) 4,34 (3,08; 4,85) 6,11 (4,22; 8,46) р1<0,001; р2=0,872; р3=0,003
Lymphocytes, % 36,47 (35,44; 38,57) 31,8 (29,65; 36,15) 34,7 (33,71; 35,78) р1<0,001; р2=0,005; р3=0,041
В-cells
(СD3-СD19+), % 
19,07 (16,84; 23,71) 12,3 (9,65; 15,1) 17,22 (13,46; 19,38) р1<0,001; р2=0,013; р3<0,001
В-cells
(СD3–СD19+), G/l
0,27 (0,19; 0,32) 0,17 (0,14; 0,32) 0,44 (0,32; 0,52) р1<0,001; р2=0,003; р3<0,001
Т-cells (СD3+СD19–), % 55,66 (52,11; 57,19) 57,8 (49,6; 61,6) 71,79 (65,52; 75,31) р1=0,300; р2<0,001; р3<0,001
Т-cells (СD3+СD19–), G/l 1,29 (1,11; 1,86) 1,31 (1,06; 1,88) 1,41 (1,06; 1,73) р1=0,230; р2<0,001; р3=0,933
T-helpers (СD3+СD4+), % 39,73 (36,23; 42,64) 29,85 (27,9; 33,15) 38,13 (36,51; 41,5) р1<0,001; р2=0,739; р3<0,001
Т-cytotoxic (СD3+СD8+), % 24,05 (21,29; 27,04) 24,25 (20,85; 28,55) 28,05 (23,43; 29,88) р1=0,966; р2=0,008; р3=0,033
Immunoregulatory index 1,56 (1,41; 1,92) 1,92 (1,11; 3,38) 1,86 (1,28; 2,35) р1<0,001; р2=0,016; р3=0,638
NK-cells  
(СD3–СD16+СD56+), % 
14,1 (12,93; 16,34) 11,3 (9,65; 13,5) 13,71 (9,71; 18,73) р1<0,001; р2=0,691; р3=0,110
T-NK-cells 
(СD3+СD16+СD56+), % 
4,48 (3,12; 6,94) 3,6 (2,6; 4,65) 2,21 (1,49; 4,28) р1<0,001; р2<0,001; р3=0,152
T-activated  
(СD3+HLA-DR+), % 
1,57 (1,25; 1,98) 3,1 (1,45; 5,1) 3,33 (1,48; 5,26) р1=0,003; р2=0,008; р3=0,925
T-activated  
(СD3+HLA-DR+), G/l
0,07 (0,04; 0,09) 0,05 (0,04; 0,06) 0,01 (0,01; 0,03) р1=0,003; р2=0,001; р3<0,001
Note: * – differences between groups by Mann-Whitney U-criterion: р1 – between the main group and comparison one; р2 – between 
the main group and control one; р3 – between the comparison group and control one
The analysis of the cellular immunity state of patients of research groups (Table 2, 3) 
demonstrated the reliable (р<0,05) changes of most indices took place on the background of the 
treatment that indicated the positive influence of the prescribed treatment. The immunoregulatory 
index and T-helpers (СD3+СD4+), % were reliable increased in the main group (р=0,001) and sta-
ble in comparison ones (р=0,682) (Table 1). At comparing the cellular immunity link in patients of 
the main and comparison groups at the end of the treatment, it was revealed, that differences were 
rather essential and reliably differed from each other in favor to indices of the main group (Table 2). 
The analysis of cellular immunity indices distribution in patients of the research groups relative to 
referent (normative) values proved the essential (р<0,05) approximation to norms in the main group 
of patients: lymphocytes (%), В-cells (СD3-СD19+) (%), T-helpers (СD3+СD4+) (%), Т-cytotoxic 
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(СD3+СD8+) (%) and T-NK-cells (СD3+СD16+СD56+) (%). The reliable approximation to referent 
values wasn’t observed in patients from the comparison group by these indices. 
The results of the study of humoral immunity indices and phagocytosis state in patients 
from the research groups at the final stage of pneumonia treatment are presented in Table 1. 
Table 3
Humoral immunity indices and phagocytosis state in patients with AnonLL at the final stage of pneumonia 
treatment 
Indices Me (25 %; 75 %) Main group n=18 Comparison group n=19 Control group n=20 Differences between groups*
Іg А, g/l 000 2,33 (1,77; 2,78) 1,85 (1,54; 1,96) 2,94 (2; 3,27) р1=0,002; р2=0,095; р3=0,001
Іg М, g/l 1,61 (1,18; 1,77) 1,14 (1; 1,46) 1,55 (1,28; 1,89) р1=0,001; р2=0,675; р3=0,004
Іg G, g/l 10,94 (9,81; 11,89) 9,77 (8,35; 12,08) 10,24 (8,58; 11,92) р1=0,359; р2=0,484; р3=0,565
Phagocytic  
activity, un 34 (25; 43) 29 (23; 33,5) 60,83 (47,55; 73,01) р1=0,039; р2<0,001; р3<0,001
Phagocytic  
number, un 4,7 (3,6; 5,1) 3,25 (2,65; 4,45) 6,57 (4,84; 8,23) р1=0,006; р2<0,001; р3<0,001
Spontaneous  
NBT-test, un 6 (5; 7) 4 (3,05; 5) 8,63 (6,33; 12,29) р1<0,001; р2=0,004; р3<0,001
Stimulated  
NBT-test, un 25 (18; 28) 33,5 (26,5; 40) 63,69 (57,51; 68,36) р1<0,001; р2<0,001; р3<0,001
Note: * – differences between groups by Mann-Whitney U-criterion: р1 – between the main group and comparison one; р2 – between 
the main group and control one; р3 – between the comparison group and control one
As we can see from the data, presented in Table 3, humoral immunity indices – IgА and 
IgM – reliably increased in the main group of observation (р<0,002 and р<0,001) in the treatment 
dynamics. IgА and IgM indices changed no reliably in patients from the comparison groups. 
The analysis of IgА and IgM indices distribution in patients from the research groups relative 
to referent (normative) values proved the essential (р<0,05) approximation to norms only in the 
main group of patients. PA and PN, spontaneous and stimulated NBT-test indices (that charac-
terized phgocytosis activity) increased in the treatment dynamics in the research groups. But PA 
and spontaneous NBT-test at the end of the treatment reliably (р<0,001) increased only in the 
main research group. The dynamics of spontaneous and stimulated NBT-tests was characterized 
by the positive dynamics (р<0,001 and р<0,001, respectively) only in the main research group. 
The reliable dynamics to normal values took place in these indices distribution also in the main 
research group, as opposite to the comparison one (р>0,05), in which result essential differences 
(р<0,001) were observed between these indices relative to the norm in research groups at the end 
of the treatment. ІgG index at the final stage of pneumonia treatment in patients of the main and 
control were not reliable (р≥0,05).
5. Discussion of research results
At studying the immune system state of patients from research groups we detected the im-
mune imbalance, deepened the CT course by practically all indices of cellular and immunity links. 
The obtained data coincide with ones of the other authors [15]. At the analysis of the obtained data 
at the end of treatment in the research groups, it was determined, that the concomitant therapy of 
the acute infectious process in lungs in both research groups led to the positive result, proved by 
reliable (р<0,05) changes of cellular and humoral immunity links of patients in the research groups. 
But comparing these indices between groups, it was determined, that they were reliably (р<0,05) 
higher in patients with the use of the immunemodeling preparation glutamyl-cysteinyl-glycine di-
sodium. It is important to accent the fact that patients from the main research group had also 
reliably increased number of T-helpers (СD3+СD4+) and immunoregulatory index. It was proved, 
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that disorders of regulatory and effective functions of immunocompetent cells in patients with 
pneumonias are characterized with the change of balance of CD4+/CD8+ lymphocytes to the side 
of decrease of the helper and prevailing suppressor effect [16]. Thus, the reception of the renew-
al of the number of T-helpers (СD3+СD4+) and decrease of the suppressor effect in patients of 
the main group prove the expedience of using the immunolodeling preparation glutamyl-cyste-
inyl-glycine disodium for the positive influence on pathogenetic links of the immune imbalance 
development at pneumonias. 
Under conditions of the immune system imbalance on the background of AL, the one 
on main tasks is the correction of diverse manefestations of the immune deficiency, including 
humoral one. It is important that IgА and IgM indices of patients of the main group differed 
not reliably from ones of the control group (р=0,095 and р=0,675), respectively; whereas they 
differed reliably в (р=0,001 and р=0,004) in patients from the control group. Thus, the anal-
ysis of IgА and IgM indices of patients from the main group testify to the reliable (р<0,005) 
approximation to indices of healthy people. IgА and IgM indices in patients of the comparison 
group didn’t approximate to referent values even at the positive dynamics. Positive reliable 
changes of the humoral immunity in patients with AnonLL at the final pneumonia treatment 
stage by IgА and IgM indices and their approximation to the indices of healthy people are the 
desirable response of the immune system in patients with pneumonias. Because it is known, 
that IgM activates the system of enzymes that take part in the immune response realization and 
have the ability to intensify phagocytosis indices. ІgА is responsible for infectious agents and 
bacterial toxins neutralization. Just these immunomodeling effects of glutamyl-cysteinyl-gly-
cine disodium were expected in this research. ІgG index dynamics in patients of the research 
groups at the final stage of pneumonia treatment were not reliable, because ІgG are so-called 
late antibodies. 
Thus, the results of the research proved the positive dynamics of indices of cellular 
and humoral immunity links and phagocytosis state in patients with pneumonias on the back-
ground of using glutamyl-cysteinyl-glycine disodium preparation. The obtained research re-
sults coincide with the data of our previous researches [17] and ones of the other authors. The 
inclusion of glutamyl-cysteinyl-glycine disodium in COPD therapy favored the growth of the 
number of mature Т-lymphocytes, Т-helpers, cytotoxic cells in peripheral blood [8]. Patients 
with out-hospital pneumonia with immunodeficiency signs at using glutamyl-cysteinyl-gly-
cine disodium also demonstrated the positive clinical effect, associated with the shortening 
of patient’s staying at hospital [11]. The researches demonstrated the effect of this preparation 
by favoring more subjectability to antibacterial preparations effect. It also favors the increase 
of CT means effectiveness by changing the activity of membrane transporters of resistance 
to chemotherapeutic preparations [19]. These effects of glutamyl-cysteinyl-glycine disodium 
were realized in our research at clinic by the decrease of days of AB load and faster return to 
the program treatment. 
According to clinical researches, glutamyl-cysteinyl-glycine disodium decreases terms of 
resorption of infiltrative and nidal changes in lungs on the background of the increase of the num-
ber of mature T-lymphocytes, T-helpers, cytotoxic cells in peripheral blood in patients with the 
specific pulmonary inflammation [11]. The positive effects of using glutamyl-cysteinyl-glycine di-
sodium are the decrease of expenditures of treatment of patients, including shortening of staying at 
hospital, decrease of reserve preparations and concomitant therapy means consumption [20].
Thus, our results that indicate the reliable positive dynamics of indices of cellular and hu-
moral immunity links and activation of indices of anti-infectious defense, persuasively testify the 
possibility of using immunomodeling preparation glutamyl-cysteinyl-glycine disodium for im-
proving the treatment schemes for patients with pneumonias at the background of AnonLL. 
Our research was realized on the small number of patients. It is caused by the malignant 
course of the main disease. Today the question as to the immunomodeling therapy use at pneumo-
nias in patients with immunity disorders, including on the background of oncological diseases of 
blood, must be the subject of a separate discussion and additional scientific researches. 
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6. Conclusions
1. The peculiarities of immunological reactivity state in patients with different forms of 
hemoblastosis, including AnonLL, become the pathogenetic background of diverse infectious com-
plications, including pneumonias that are often causes of death. That is why the strategy of using 
only ethiotropic therapy at pneumonias in patients with AnonLL doesn’t lead to expecting results. 
The necessity of improving treatment schemes of pneumonias on the background of AnonLL con-
ditions the inclusion of preparations with the immunomodeling effect on the different immunity 
links of a patient. 
2. The analysis of the research results proved the positive dynamics of indices of the cellular 
immunity link of patients with AnonLL on the background of the pneumonia treatment, manifested 
by reliable (р<0,05) changes by almost all indices of the cellular immunity in the research group 
with the use of immunomodeling preparation glutamyl-cysteinyl-glycine disodium. The approxi-
mation of the immunoregulatory index and other indices of the cellular immunity link of patients 
with AnonLL of the main group to the ones of healthy people is the desirable response of the im-
mune system of patients with pneumonias at the background of AnonLL. 
3. The results of this research proved the positive dynamics of humoral immunity indices by 
reliable changes of ІgА, responsible for infectious agents and bacterial toxins neutralization, and 
ІgМ, that activates phagocytosis in patients with AnonLL at using immunomodeling preparation 
glutamyl-cysteinyl-glycine disodium in the pneumonia treatment scheme. 
4. The increase of indices of phagocytic activity, phagocytic number and NBT-test in 
patients with AnonLL with pneumonias at using glutamyl-cysteinyl-glycine disodium testifies 
to the intensification of neutrophil granulocytes activity at system bacterial infectious diseas-
es – pneumonias. This fact proves the possibility of improving pneumonia treating schemes in 
patients with severe immunity disorders using the immunomodeling preparation glutamyl-cys-
teinyl-glycine disodium. 
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